Ozempic vs. compounded semaglutide: what the comparison videos miss

What's this video probably claiming?

Levity is a telehealth weight loss company that markets compounded semaglutide. A side-by-side comparison video from this creator almost certainly frames compounded semaglutide as a lower-cost, functionally similar alternative to brand-name Ozempic or Wegovy. Expect claims about equivalent active ingredients, significant price differences, and convenience. The video likely positions compounded versions favorably on cost, availability during shortage periods, and perhaps flexibility in dosing. Telehealth platforms running these comparisons have a clear financial interest in promoting compounded options, which is worth flagging before evaluating any specific claim. The framing of "which might be best for you" is the kind of language that sounds consumer-friendly but often obscures important regulatory and clinical distinctions that a 60-second TikTok cannot adequately address.

What does the science actually show?

Branded semaglutide products (Ozempic, Wegovy) have been studied in large, rigorous trials. The STEP 1 trial (Wilding et al., 2021, NEJM) showed 2.4 mg weekly semaglutide produced mean body weight reduction of 14.9% over 68 weeks versus 2.4% for placebo. The SUSTAIN trial series established the pharmacokinetic and safety profile of 0.5 mg and 1.0 mg doses for type 2 diabetes. Compounded semaglutide, by contrast, has no equivalent Phase 3 trial data. The FDA does not review compounded drugs for efficacy or safety before they reach patients. The active molecule, semaglutide, is the same on paper, but excipients, sterility standards, concentration accuracy, and shelf stability in compounded preparations are not independently verified. A 2023 analysis from the Alliance for Pharmacy Compounding acknowledged variable potency as a real concern. That is not a minor footnote.

Where does the social media noise diverge from clinical reality?

The biggest distortion in compounded-versus-brand comparisons is the implied equivalency. Creators often say the "same active ingredient" as if pharmaceutical manufacturing were just a recipe anyone can follow. It is not. Novo Nordisk's semaglutide uses a specific fatty acid chain modification that affects half-life and binding affinity. Generic small molecules like metformin are easier to replicate. Peptides are not. The FDA has repeatedly warned about compounded semaglutide quality, issuing alerts in 2023 and 2024 about products using semaglutide sodium or acetate salt forms rather than the base form used in approved products. These are chemically distinct. Additionally, dosing flexibility claims in these videos sometimes gesture toward personalized medicine but can actually mean less standardization and more room for error. Cost comparisons also rarely account for the monitoring and follow-up infrastructure embedded in brand-name prescribing pathways.

What should you actually know?

Compounded semaglutide was legally permitted during the FDA-declared shortage period for Ozempic and Wegovy. The FDA removed Wegovy from the shortage list in early 2025 and Ozempic shortly after, which means the legal basis for widespread compounding of these drugs has narrowed considerably. Patients currently on compounded versions may need to transition. That is a real clinical conversation to have with a prescriber, not a TikTok. If you are considering any semaglutide product, the questions that actually matter are: Is this from a 503B outsourcing facility with FDA registration? What is the verified concentration? Who is monitoring your cardiac, renal, and GI response? A comparison chart cannot answer those questions. Price is a legitimate barrier to access, and that is worth acknowledging, but cost alone is not a safety or efficacy argument.